Shares of Sun Pharmaceutical Industries Ltd. 524715 inched up 0.08% to 1,785.30 Indian rupees Monday, on what proved to be an ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...

In New Jersey, new initiatives support investment and job growth in the artificial intelligence and film and digital media ...

Sun Pharmaceutical Industries Ltd. closed 10.79% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, are recalling seizure treatments, ...

Sun Pharmaceuticals Industries Ltd. on Monday, March 10, said it will acquire a Nasdaq-listed immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc.

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun Pharma’s oncology portfolio with FDA-approved UNLOXCYT for advanced cutaneous ...

The acquisition will be for an upfront cash payment of 4.10 dollars per share, aggregating up to 355 million dollars, the Sun Pharmaceutical Industries Ltd said on March 10. The deal, subject to ...

Sun Pharma is going to acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share, an official statement from the company revealed on Monday. The deal will come up to $355 million ...

(Reuters) -India’s Sun Pharmaceutical Industries said on Monday that it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 ...

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares opened today at $1.14. Effectively assess a stock ...

Sun Pharma will acquire Checkpoint Therapeutics for $4.10 per share, with a potential additional $0.70 CVR. FDA-approved Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cSCC in ...